10 results on '"Autoantibodies therapeutic use"'
Search Results
2. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
- Author
-
Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, and Reid P
- Subjects
- Humans, Female, Middle Aged, Male, Retrospective Studies, Autoantibodies therapeutic use, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms drug therapy, Arthritis
- Abstract
Background: Side effects of immune checkpoint inhibitors (ICIs), called immune-related adverse events (irAEs), closely resemble primary autoimmune or rheumatic diseases. We aimed to understand the clinical utility of rheumatic autoantibodies (rhAbs) for diagnosing irAEs., Patients and Methods: Patients without pre-existing autoimmune disease (pAID) who had cancer treated with ICI(s) treatment from 1/1/2011 to 12/21/2020 and a rhAb checked were retrospectively identified. Logistic regression assessed associations between autoantibodies and irAEs, cancer outcome, and survival. Specificity, sensitivity, and positive/negative predictive values (PPV, NPV) were estimated for key rhAbs and ICI-arthritis. Kaplan-Meier analyzed objective response rate (ORR) and overall survival (OS)., Results: A total of 2662 patients were treated with≥1 ICIs. One hundred and thirty-five without pAID had ≥ 1 rhAb tested. Of which 70/135(52%) were female; median age at cancer diagnosis was 62 years with most common cancers: melanoma (23%) or non-small cell lung cancer (21%), 96/135 (75%) were anti-PD1/PDL1 treated. Eighty had a rhAb ordered before ICI, 96 after ICI, and 12 before and after. Eighty-two (61%) experienced an irAE, 33 (24%) with rheumatic-irAE. Pre-ICI RF showed significant association with rheumatic-irAEs (OR = 25, 95% CI, 1.52-410.86, P = .024). Pre- and post-ICI RF yielded high specificity for ICI-arthritis (93% and 78%), as did pre- and post-ICI CCP (100% and 91%). Pre-ICI RF carried 93% NPV and pre-ICI CCP had 89% PPV for ICI-arthritis. No variables were significantly correlated with ORR. Any-type irAE, rheumatic-irAE and ICI-arthritis were all associated with better OS (P = .000, P = .028, P = .019)., Conclusions: Pre-ICI RF was associated with higher odds of rheumatic-irAEs. IrAEs had better OS; therefore, clinical contextualization for rhAbs is critical to prevent unnecessary withholding of lifesaving ICI for fear of irAEs., (© The Author(s) 2023. Published by Oxford University Press.)
- Published
- 2023
- Full Text
- View/download PDF
3. Characteristics and Outcomes of Autoimmune Hepatitis from a Tertiary Paediatric Centre, Cape Town, South Africa.
- Author
-
Yassin S, De Lacy R, Pillay K, and Goddard E
- Subjects
- Autoantibodies immunology, Autoantibodies therapeutic use, Azathioprine therapeutic use, Biopsy, Child, Child, Preschool, Cholangitis, Sclerosing drug therapy, Cholangitis, Sclerosing immunology, Female, Glucocorticoids therapeutic use, Hepatitis, Autoimmune drug therapy, Hepatitis, Autoimmune immunology, Humans, Liver pathology, Male, Prednisolone therapeutic use, South Africa, Treatment Outcome, Cholangiopancreatography, Magnetic Resonance methods, Cholangitis, Sclerosing diagnostic imaging, Hepatitis, Autoimmune diagnosis, Immunosuppressive Agents therapeutic use
- Abstract
Objectives: To describe the clinical characteristics, biochemical and histological features, outcomes and predictors of prognosis of children with autoimmune hepatitis (AIH) from a paediatric centre in South Africa., Methods: Thirty-nine children diagnosed with AIH at Red Cross War Memorial Children's Hospital between 2005 and 2015 were included. Relevant patient's data were retrieved from the hospital's medical records and database. Liver biopsy slides were reviewed. Ethical approval was obtained. Data were analysed using SPSS., Results: Females were 29 (74%). Mean age at presentation was 7.27 ± 3.35 years and the mean follow-up was 4.5 ± 2.4 years. Jaundice was present in 97% of patients at presentation. An acute presentation was observed in 26 (67%) even though cirrhosis was detected in 22 (56%). Autoantibody screening was completed in 35 patients, 20 (57%) were AIH-1, 1 (3%) was AIH-2 and 14 (40%) were seronegative AIH. Of the 25 patients who underwent magnetic resonance cholangiography 17 (68%) had associated autoimmune sclerosing cholangitis. The remission rate was 79%. However, 11 children relapsed later. One child required liver transplantation and one demised. Seronegative and seropositive patients have comparable characteristics and outcomes. While a higher alanine transaminase (ALT) level at presentation is a significant predictor of remission, a lower ALT level and cirrhosis are significant risk factors for unfavourable outcome. Overall survival rate was 97%., Conclusion: AIH responds well to therapy with excellent survival. Hence, it should be considered in any child presenting with viral screen negative hepatitis and start therapy timeously to prevent disease progression., (© The Author(s) [2020]. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
4. Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
- Author
-
Davis B, Shen Y, Poon CC, Luchman HA, Stechishin OD, Pontifex CS, Wu W, Kelly JJ, and Blough MD
- Subjects
- Aged, Autoantibodies therapeutic use, Brain Neoplasms pathology, Cell Proliferation drug effects, Female, Genetic Testing, Glioblastoma pathology, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Brain Neoplasms genetics, DNA Copy Number Variations genetics, Genome, Human, Glioblastoma genetics, Neoplastic Stem Cells pathology
- Abstract
Background: Glioblastoma (GBM) is a fatal cancer that has eluded major therapeutic advances. Failure to make progress may reflect the absence of a human GBM model that could be used to test compounds for anti-GBM activity. In this respect, the development of brain tumor-initiating cell (BTIC) cultures is a step forward because BTICs appear to capture the molecular diversity of GBM better than traditional glioma cell lines. Here, we perform a comparative genomic and genetic analysis of BTICs and their parent tumors as preliminary evaluation of the BTIC model., Methods: We assessed single nucleotide polymorphisms (SNPs), genome-wide copy number variations (CNVs), gene expression patterns, and molecular subtypes of 11 established BTIC lines and matched parent tumors., Results: Although CNV differences were noted, BTICs retained the major genomic alterations characteristic of GBM. SNP patterns were similar between BTICs and tumors. Importantly, recurring SNP or CNV alterations specific to BTICs were not seen. Comparative gene expression analysis and molecular subtyping revealed differences between BTICs and GBMs. These differences formed the basis of a 63-gene expression signature that distinguished cells from tumors; differentially expressed genes primarily involved metabolic processes. We also derived a set of 73 similarly expressed genes; these genes were not associated with specific biological functions., Conclusions: Although not identical, established BTIC lines preserve the core molecular alterations seen in their parent tumors, as well as the genomic hallmarks of GBM, without acquiring recurring BTIC-specific changes., (© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF
5. Gammaglobulins, autoantibodies, therapeutic antibodies and anti-drug antibodies in rheumatoid arthritis.
- Author
-
Gottenberg JE
- Subjects
- Animals, Antibodies, Monoclonal immunology, Arthritis, Rheumatoid immunology, Autoantibodies immunology, Humans, Tumor Necrosis Factor-alpha immunology, gamma-Globulins immunology, Antibodies, Monoclonal therapeutic use, Arthritis, Rheumatoid therapy, Autoantibodies therapeutic use, gamma-Globulins therapeutic use
- Published
- 2014
- Full Text
- View/download PDF
6. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition.
- Author
-
Geis C, Weishaupt A, Hallermann S, Grünewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Üçeyler N, Fouquet W, Gerlach M, Meinck HM, Sirén AL, Sigrist SJ, Toyka KV, Heckmann M, and Sommer C
- Subjects
- Aged, Animals, Autoantibodies administration & dosage, Autoantibodies physiology, Cells, Cultured, Endocytosis immunology, Female, Humans, Immunization, Passive methods, Immunoglobulin G administration & dosage, Immunoglobulin G physiology, Immunoglobulin G therapeutic use, Inhibitory Postsynaptic Potentials physiology, Injections, Spinal, Mice, Mice, Knockout, Middle Aged, Rats, Rats, Inbred Lew, Stiff-Person Syndrome pathology, gamma-Aminobutyric Acid deficiency, Autoantibodies therapeutic use, Nerve Tissue Proteins immunology, Neural Inhibition immunology, Stiff-Person Syndrome immunology, Stiff-Person Syndrome therapy, gamma-Aminobutyric Acid metabolism
- Abstract
Synaptic inhibition is a central factor in the fine tuning of neuronal activity in the central nervous system. Symptoms consistent with reduced inhibition such as stiffness, spasms and anxiety occur in paraneoplastic stiff person syndrome with autoantibodies against the intracellular synaptic protein amphiphysin. Here we show that intrathecal application of purified anti-amphiphysin immunoglobulin G antibodies induces stiff person syndrome-like symptoms in rats, including stiffness and muscle spasms. Using in vivo recordings of Hoffmann reflexes and dorsal root potentials, we identified reduced presynaptic GABAergic inhibition as an underlying mechanism. Anti-amphiphysin immunoglobulin G was internalized into neurons by an epitope-specific mechanism and colocalized in vivo with presynaptic vesicular proteins, as shown by stimulation emission depletion microscopy. Neurons from amphiphysin deficient mice that did not internalize the immunoglobulin provided additional evidence of the specificity in antibody uptake. GABAergic synapses appeared more vulnerable than glutamatergic synapses to defective endocytosis induced by anti-amphiphysin immunoglobulin G, as shown by increased clustering of the endocytic protein AP180 and by defective loading of FM 1-43, a styryl dye used to label cell membranes. Incubation of cultured neurons with anti-amphiphysin immunoglobulin G reduced basal and stimulated release of γ-aminobutyric acid substantially more than that of glutamate. By whole-cell patch-clamp analysis of GABAergic inhibitory transmission in hippocampus granule cells we showed a faster, activity-dependent decrease of the amplitude of evoked inhibitory postsynaptic currents in brain slices treated with antibodies against amphiphysin. We suggest that these findings may explain the pathophysiology of the core signs of stiff person syndrome at the molecular level and show that autoantibodies can alter the function of inhibitory synapses in vivo upon binding to an intraneuronal key protein by disturbing vesicular endocytosis.
- Published
- 2010
- Full Text
- View/download PDF
7. Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigen.
- Author
-
Vincent A
- Subjects
- Autoantibodies administration & dosage, Autoantibodies therapeutic use, ELAV Proteins immunology, Humans, Injections, Spinal, Nerve Tissue Proteins immunology, Stiff-Person Syndrome therapy, Autoantibodies physiology, Autoantigens immunology, Immunization, Passive methods, Intracellular Fluid immunology, Stiff-Person Syndrome immunology
- Published
- 2010
- Full Text
- View/download PDF
8. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation.
- Author
-
Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, and Shoenfeld Y
- Subjects
- Animals, Autoantibodies therapeutic use, Humans, Immunity, Innate immunology, Immunoglobulins, Intravenous immunology, Multiple Sclerosis drug therapy, Autoimmunity immunology, Immunoglobulins immunology, Inflammation immunology, Neoplasms immunology
- Abstract
Natural antibodies are produced by B lymphocytes in the absence of external antigen stimulation. With their ability to recognize self, altered self and foreign antigens, they comprise an important first-line defence against invading pathogens, but are also important for tissue homeostasis. By recognizing oligosaccharides expressed on tumour cells and modified cell surface structures accompanying necrosis, natural antibodies have an important anti-tumorigenic function. IVIg contains a wide spectrum of specificities presented in normal plasma including natural antibodies and has been shown to exert inhibitory effects on tumour cells through a subfraction of anti-vascular endothelial growth factor immunoglobulin (Ig)G antibodies with anti-angiogenic properties. IgA antibodies also have potent immunomodulatory properties, being able to both induce and suppress immune responses. IgA-mediated inhibitory function is able to inhibit several inflammatory diseases including asthma and glomerulonephritis. Autoantibodies of the IgM type, on the other hand, have shown promising results in the treatment of multiple sclerosis. These autoantibodies promote remyelination rather than modulating inflammation. Oxidation-specific epitopes, as found in atherosclerotic lesions and on apoptotic cells, comprise one important target of natural antibodies. By recognizing these epitopes, natural antibodies neutralize proinflammatory responses and mediate atheroprotection.
- Published
- 2009
- Full Text
- View/download PDF
9. Very early steroid withdrawal in simultaneous pancreas-kidney transplants.
- Author
-
Aoun M, Eschewege P, Hamoudi Y, Beaudreuil S, Duranteau J, Cheisson G, Noel C, Benoit G, Charpentier B, and Durrbach A
- Subjects
- Acute Disease, Adult, Autoantibodies therapeutic use, Drug Therapy, Combination, Female, Follow-Up Studies, Glucocorticoids therapeutic use, Graft Rejection epidemiology, Graft Survival, Humans, Immunosuppressive Agents therapeutic use, Incidence, Male, Mycophenolic Acid analogs & derivatives, Mycophenolic Acid therapeutic use, Prodrugs, Prospective Studies, Survival Rate, Tacrolimus therapeutic use, Time Factors, Treatment Outcome, Diabetes Mellitus, Type 1 surgery, Glucocorticoids administration & dosage, Graft Rejection prevention & control, Kidney Transplantation methods, Pancreas Transplantation methods
- Abstract
Background: Simultaneous pancreas-kidney (SPK) transplantation is an effective treatment for patients suffering from type 1 diabetes mellitus. Conventional immunosuppressive treatments include steroids that may induce insulin resistance and are responsible for many side effects. In de novo SPK, early withdrawal of corticosteroids may be an important issue., Methods: A total of 24 consecutive patients with type 1 diabetes mellitus had been treated by SPK transplantation. All of them had a short induction therapy with anti-thymoglobulin (ATG) and steroids for only 4 days, association with CellCept and tacrolimus. The rate of acute rejection, graft and patient survival and side effects have been analysed., Results: Patient and kidney survival was 100% and the pancreas survival was 95.6% at 1 year. The rate of acute rejection of kidney and pancreas was 4.2% and 8.3% at 6 months, respectively. The mean serum creatinine was 98.9+/-19.6 micromol/l and the mean HbA1c concentration was 5.1%+/-0.5% at 6 months. Only four patients developed a cytomegalovirus primo-infection, associated in one case with pneumonia, whereas 75% of patients developed a bacterial infection. Because of the occurrence of leucopenia and/or diarrhoea, CellCept has been dramatically decreased in 33% of cases and required the re-introduction of steroids., Conclusion: A short induction with ATG and steroids associated with a chronic therapy with CellCept and tacrolimus is safe and efficient in preventing acute renal rejection in SPK.
- Published
- 2007
- Full Text
- View/download PDF
10. The antiphospholipid syndrome. Clinical correlations, cutaneous features, mechanism of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolipin antibodies.
- Author
-
Stephens CJ
- Subjects
- Autoantibodies therapeutic use, Cardiolipins therapeutic use, Female, Humans, Lupus Coagulation Inhibitor therapeutic use, Syndrome, Thrombosis therapy, Autoantibodies analysis, Cardiolipins immunology, Lupus Coagulation Inhibitor analysis, Skin Diseases immunology, Thrombosis immunology
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.